2020-05-11 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: NM case counts. Navajo Nation documentary. Medicaid reimbursement increase. Excess NYC mortality. German R0\u3e1. Chile COVID-19 certificates. High female incidence in Quebec. Swab 3D printing. Evidence lacking school reopening. Cloth mask review. WHO 2nd wave warning. Higher mortality in minorities. Environmental transmission controls. Behavior change. Correctional environment guidelines. Wuhan hospital transformation. Maximizing GI training. Threat and conformity. Recommendations on managing COVID-19 (first Italian SARS patients), and obesity and metabolic syndrome. Guidelines for neurologists. Ethics of off-label drugs use. Abbott antibody test approval. CRISPR test FDA approval. Viral sample inactivation. HCQ+azithromycin no benefit. Public-Private partnership for clinical trials. Drug repurposing. Cancer patient considerations. 35 new COVID-19 trials. Hyperinflammatory shock in children. Symptom app

2020-04-20 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

Executive Summary: NM highlights. Immigration detention centers. US outbreak perceptions. States lockdown protests. Drones sample transport. Black market antivirals. NZ eases lockdown. Germany partial reopening. Low temperature/humidity favors transmission. Wastewater epidemiology. Contact tracing privacy. D-dimer severity prediction. China fatality factors. Group testing. High throughput testing. Pet testing. WHO misinformation countermeasure. WHO produce washing. Public health strategies. Fellows education adaptations. Mental health priorities. Practice guidelines: immunocompromised cancer patients, IBD, tracheostomy, trauma surgery, neurovascular management, head & neck cancer surgery, long-term care, and respiratory home care. Remdesivir macaque clinical benefit. Hydroxychloroquine meta-analysis. Heparin anticoagulant therapy. Hypothiocyanite hypothesis. 36 new clinical trials. Neutrophil lymphocyte ratio. Blood coagulation. Viral organ system reach. Optimal antiviral dosing